The increase in price target from $35 to $44 by RBC Capital indicates a positive outlook on Viridian Therapeutics' future performance. Maintaining an Outperform rating suggests that the analyst expects the stock to perform better than the market average, which is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.